About Aileron Therapeutics (NASDAQ:ALRN)
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ALRN
- CUSIP: N/A
- Web: www.aileronrx.com
Capitalization:- Market Cap: $199.83 million
- Outstanding Shares: 14,715,000
Average Prices:- 50 Day Moving Avg: $13.23
- 200 Day Moving Avg: $12.84
- 52 Week Range: $10.37 - $15.48
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.26
- P/E Growth: 0.00
Debt:- Current Ratio: 2.19%
- Quick Ratio: 2.19%
Misc:- Average Volume: 50,311 shs.
Frequently Asked Questions for Aileron Therapeutics (NASDAQ:ALRN)
What is Aileron Therapeutics' stock symbol?
Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."
When will Aileron Therapeutics make its next earnings announcement?
Where is Aileron Therapeutics' stock going? Where will Aileron Therapeutics' stock price be in 2017?
4 equities research analysts have issued 1 year price targets for Aileron Therapeutics' shares. Their forecasts range from $19.00 to $20.00. On average, they anticipate Aileron Therapeutics' stock price to reach $19.33 in the next year. View Analyst Ratings for Aileron Therapeutics.
Who are some of Aileron Therapeutics' key competitors?
Some companies that are related to Aileron Therapeutics include Kura Oncology (KURA), uniQure N.V. (QURE), Corbus Pharmaceuticals Holdings (CRBP), Mersana Therapeutics (MRSN), AVEO Pharmaceuticals (AVEO), Merus N.V. (MRUS), CymaBay Therapeutics (CBAY), Urogen Pharma (URGN), GlycoMimetics (GLYC), NantKwest (NK), Ra Pharmctl (RARX), BioSpecifics Technologies Corp (BSTC), Bellicum Pharmaceuticals (BLCM), Geron Corporation (GERN), Akebia Therapeutics (AKBA), Edge Therapeutics (EDGE), ObsEva SA (OBSV) and Forward Pharma A/S (FWP).
Who are Aileron Therapeutics' key executives?
Aileron Therapeutics' management team includes the folowing people:
- Joseph A. Yanchik III, Esq., President, Chief Executive Officer, Director
- Evan Lippman, Chief Financial Officer and Business Officer, Senior Vice President
- Manuel C. Aivado, Senior Vice President and Chief Medical Officer
- D. Allen Annis Ph.D., Vice President - Biophysical and Analytical Technologies
- Seth L. Harrison M.D., Director
When did Aileron Therapeutics IPO?
(ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
How do I buy Aileron Therapeutics stock?
Shares of Aileron Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aileron Therapeutics' stock price today?
One share of Aileron Therapeutics stock can currently be purchased for approximately $13.58.
MarketBeat Community Rating for Aileron Therapeutics (NASDAQ ALRN)MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Aileron Therapeutics (NASDAQ:ALRN)Earnings History by Quarter for Aileron Therapeutics (NASDAQ ALRN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/9/2017 | | | | | | | | |
| 2/8/2013 | Q3 2012 | | ($0.07) | | | View | N/A |  |
| 11/12/2012 | Q312 | | ($0.03) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Aileron Therapeutics (NASDAQ:ALRN)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 2 | ($0.44) | ($0.42) | ($0.43) |
| Q3 2017 | 2 | ($0.36) | ($0.32) | ($0.34) |
| Q4 2017 | 2 | ($0.39) | ($0.35) | ($0.37) |
(Data provided by Zacks Investment Research)
Dividend History for Aileron Therapeutics (NASDAQ:ALRN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aileron Therapeutics (NASDAQ:ALRN)Insider Ownership Percentage: 68.10%
Institutional Ownership Percentage: 12.30%
Insider Trades by Quarter for Aileron Therapeutics (NASDAQ:ALRN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/5/2017 | Cvf, Llc | Major Shareholder | Buy | 180,000 | $15.00 | $2,700,000.00 | |
| 7/5/2017 | Lilly Ventures Fund I Llc | Insider | Buy | 250,000 | $15.00 | $3,750,000.00 | |
| 7/5/2017 | Reinhard J Ambros | Director | Buy | 266,667 | $15.00 | $4,000,005.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Aileron Therapeutics (NASDAQ:ALRN)
Latest Headlines for Aileron Therapeutics (NASDAQ:ALRN)
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Analysts Set $19.33 Target Price for Aileron Therapeutics, Inc. (ALRN)
www.americanbankingnews.com - October 16 at 12:52 PM |
 | Boston biotech developing obesity drug pulls down $120M in IPO
finance.yahoo.com - October 10 at 2:53 AM |
| Zacks: Aileron Therapeutics, Inc. (ALRN) Given $19.33 Average Price Target by Brokerages
www.americanbankingnews.com - October 7 at 6:50 PM |
| Aileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell Microcap Indexes
finance.yahoo.com - September 19 at 3:46 PM |
| Analysts Set $19.33 Target Price for Aileron Therapeutics Inc (ALRN)
www.americanbankingnews.com - September 18 at 6:38 PM |
 | TTOO Rallies For 2nd Day, SAGE's STATUS Flops, ICPT Warns Of Ocaliva Overdosing
www.nasdaq.com - September 13 at 4:56 PM |
| Aileron Therapeutics, Inc. (ALRN) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - September 11 at 8:36 PM |
| Aileron Therapeutics, Inc. (ALRN) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - September 2 at 12:36 PM |
 | Aileron Therapeutics (ALRN) Announces Presentation of Preclinical Data with ALRN-6924 at ISEH
www.streetinsider.com - August 25 at 1:33 AM |
| Aduro Biotech (ADRO) and AILERON THERAP (ALRN) Head-To-Head Analysis
www.americanbankingnews.com - August 21 at 10:26 AM |
| Aileron Therap (ALRN) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - August 11 at 6:20 PM |
| Aileron Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 5:10 PM |
| Aileron Therapeutics to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 4:45 PM |
| AILERON THERAP's (NASDAQ:ALRN) Quiet Period Will Expire on August 8th
www.americanbankingnews.com - August 1 at 12:28 PM |
| Aileron Therap (ALRN) Expected to Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - July 31 at 6:32 PM |
| Equities Analysts Set Expectations for Aileron Therap's Q2 2017 Earnings (NASDAQ:ALRN)
www.americanbankingnews.com - July 26 at 9:25 AM |
| Research Analysts Offer Predictions for Aileron Therap's Q2 2017 Earnings (ALRN)
www.americanbankingnews.com - July 26 at 9:24 AM |
| Aileron Therap (NASDAQ:ALRN) Earns Outperform Rating from Analysts at William Blair
www.americanbankingnews.com - July 24 at 11:01 AM |
| [$$] Novartis, Glaxo and Lilly Bigly Back New Biotech
finance.yahoo.com - July 19 at 4:55 PM |
| Aileron Therap (NASDAQ:ALRN) Insider Lilly Ventures Fund I. Llc Acquires 250,000 Shares
www.americanbankingnews.com - July 7 at 10:42 PM |
| Aileron Therapeutics Announces Pricing of Initial Public Offering
finance.yahoo.com - July 7 at 5:28 AM |
| Here's the Latest on Four New Biotech IPOs
finance.yahoo.com - July 7 at 5:28 AM |
| Aileron Therapeutics Inc (ALRN) Director Buys $4,000,005.00 in Stock
www.americanbankingnews.com - July 5 at 10:24 PM |
| Aileron Therapeutics Inc (ALRN) Major Shareholder Acquires $2,700,000.00 in Stock
www.americanbankingnews.com - July 5 at 10:22 PM |
Aileron Therapeutics (ALRN) Chart for Saturday, October, 21, 2017
